Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the field of melanoma.
Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma
September 21st 2023Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.
Read More
2 Clarke Drive
Cranbury, NJ 08512